Sensitivity of phenotypic susceptibility analyses for nonthymidine nucleoside analogues conferred by K65R or M184V in mixtures with wild-type HIV-1

Journal of Infectious Diseases

Volumn 199, Issue 1, 2009, Pages 84-88

  Underwood, Mark R ^a   Ross, Lisa L ^a   Irlbeck, David M ^a   Gerondelis, Peter ^a   Rouse, Elizabeth ^a   St Clair, Marty H ^a   Trinh, Lan ^b   Parkin, Neil ^b   Lanier, E Randall ^a,c  

^a GLAXOSMITHKLINE   (United States)

^b MONOGRAM BIOSCIENCES   (United States)

^c Chimerix Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; DIDANOSINE; LAMIVUDINE; TENOFOVIR;

ARTICLE; CONTROLLED STUDY; DRUG SENSITIVITY; GENE MUTATION; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; VIRUS ISOLATION;

ADENINE; ANTI-HIV AGENTS; DIDANOSINE; DIDEOXYNUCLEOSIDES; DRUG THERAPY, COMBINATION; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; LAMIVUDINE; PHENOTYPE; PHOSPHONIC ACIDS; PLASMIDS; VIRAL LOAD;

EID: 58749109626     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/595296     Document Type: Article

References (11)

1. Delaunay C, Brun-Vezinet F, Landman R, et al. Comparative selection of the K65R and M184V/I mutations in human immunodeficiency virus type 1-infected patients enrolled in a trial of first-line triple-nucleoside analog therapy (Tonus IMEA 021). J Virol 2005; 79:9572-8.
2. Gallant JE, Rodriguez AE, Weinberg WG, et al. Early virologic nonresponse to tenofovir, abacavir, and lamivudine in HIV-infected antiretroviral-naive subjects. J Infect Dis 2005; 192:1921-30.
3. Jemsek J, Hutcherson P, Harper E. Poor virologic responses and early emergence of resistance in treatment naive, HIV-infected patients receiving a once daily triple nucleoside regimen of didanosine, lamivudine, and tenofovir DF [abstract 51]. In: Program and abstracts of the 11th Conference on Retroviruses and Opportunistic Infections (San Francisco). 2004.
4. Khanlou H, Yeh V, Guyer B, Farthing C. Early virologic failure in a pilot study evaluating the efficacy of therapy containing once-daily abacavir, lamivudine, and tenofovirDFin treatment-naive HIV-infected patients. AIDS Patient Care STDS 2005; 19:135-40.
5. Landman R, Descamps D, Peytavin G, et al. Early virologic failure and rescue therapy of tenofovir, abacavir, and lamivudine for initial treatment of HIV-1 infection: TONUS study. HIV Clin Trials 2005; 6:291-301.
6. Hellman N, Johnson P, and Petropoulos C. Validation of the performance characteristics of a novel, rapid phenotypic drug susceptibility assay, PhenoSenseHIV. Antivir Ther 1999; 4(Suppl 1):S1-34.
7. Hawkins T, Veikley W, St. Claire RL III, Guyer B, Clark N, Kearney BP. Intracellular pharmacokinetics of tenofovir diphosphate, carbovir triphosphate, and lamivudine triphosphate in patients receiving triplenucleoside regimens. J Acquir Immune Defic Syndr 2005; 39:406-11.
8. Lanier ER, Hazen R, Ross L, Freeman A, Harvey R. Lack of antagonism between abacavir, lamivudine, and tenofovir against wild-type and drug-resistant HIV-1. J Acquir Immune Defic Syndr 2005; 39:519-22.
9. Ray AS, Myrick F, Vela JE, et al. Lack of a metabolic and antiviral drug interaction between tenofovir, abacavir and lamivudine. Antivir Ther 2005; 10:451-7.
10. Parkin NT, Lie YS, Hellmann N, et al. Phenotypic changes in drug susceptibility associated with failure of human immunodeficiency virus type 1 (HIV-1) triple combination therapy. J Infect Dis 1999; 180:865-70.
11. Melby T, Tortell S, Thorborn D, et al. Time to appearance of NRTI-associated mutations and response to subsequent therapy for patients on failing ABC/COM [abstract 448]. In: Program and abstracts of the 8th Conference on Retroviruses and Opportunistic Infections (Chicago). 2001.